The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.

Q2 2025 Results Conference Call May 8, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor Relations ...

Understand how semaglutide shows strong benefits in MASH treatment, improving liver health and reducing weight.

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

Novo Nordisk’s oral Wegovy pill for chronic weight loss is under FDA review. If approved, it would be the first oral GLP-1 ...

The international study led by a Virginia Commonwealth University researcher found the medication semaglutide, commonly known ...

A major international study has found that semaglutide, a drug already used to treat type 2 diabetes and obesity, can ...

Weight-loss surgeries for adolescents increased 15% in the U.S. between 2021 and 2023, even as the Food and Drug ...

Wegovy (semaglutide) could offer a new option to treat severe liver disease based on new clinical trial evidence. The GLP-1 ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

An international study led by the director of Virginia Commonwealth University’s liver institute suggests that the substance in Ozempic and Wegovy can halt and even reverse a ...

Understanding the complex hormonal science behind weight loss injections - and why they must remain strictly ...